China's FDA Issues Revised GMP Draft Guideline Following Industry Comments; Expects Compliance To Come In Stages
This article was originally published in The Pink Sheet Daily
"It will be interesting to see how much of a grace period is given for manufacturers to meet standards, or whether certain manufacturers will be 'grandfathered' under old rules," industry consultant says.
You may also be interested in...
USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis
The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis
SHANGHAI - China's State FDA recently published a new draft version of Good Manufacturing Practice guidelines for pharmaceuticals on its website for public comment
China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys
SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems